Cargando…
Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview
Immunocompromised (IC) persons are at increased risk for herpes zoster (HZ) and its complications, mainly due to impairment of cell-mediated immunity (CMI). The adjuvanted recombinant zoster vaccine (RZV) demonstrated efficacy against HZ in autologous hematopoietic stem cell transplant (auto-HSCT) r...
Autores principales: | Dagnew, Alemnew F., Vink, Peter, Drame, Mamadou, Willer, David O., Salaun, Bruno, Schuind, Anne E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8827627/ https://www.ncbi.nlm.nih.gov/pubmed/34190658 http://dx.doi.org/10.1080/21645515.2021.1930846 |
Ejemplares similares
-
4. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults
por: Dagnew, Alemnew F, et al.
Publicado: (2020) -
Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials
por: López-Fauqued, Marta, et al.
Publicado: (2021) -
37. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine (RZV) in Immunocompromised Populations: an Overview of 6 Trials
por: Fauqued, Marta Lopez, et al.
Publicado: (2020) -
The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine
por: Dagnew, Alemnew F, et al.
Publicado: (2020) -
Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trials
por: Kim, Joon Hyung, et al.
Publicado: (2023)